After MindMed’s up-listing, the company has been facing a lot of instability and turbulence in the past few months and years. It has been struggling to establish stability in a sector that is still struggling.
Data from a Phase 2 clinical trial involving LSD-assisted psychotherapy show LSD as effective treatment for Major Depressive Disorder.
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Psychedelic stock MindMed enters free fall as news of a private equity offering of common stock spooks retail investors
In the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split with Fibonacci numbers
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
Does microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.